Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD - PubMed
12 hours ago
- #EGFR-mutated NSCLC
- #Osimertinib
- #Datopotamab deruxtecan
- ORCHARD is a phase II study evaluating osimertinib plus datopotamab deruxtecan (Dato-DXd) in EGFR-mutated advanced NSCLC patients post-progression on first-line osimertinib.
- Patients received osimertinib (80 mg daily) plus Dato-DXd (4 or 6 mg/kg every 3 weeks). Primary endpoint was objective response rate (ORR).
- Confirmed ORR was 43% (4 mg/kg) and 36% (6 mg/kg). Median PFS was 9.5 and 11.7 months, respectively.
- Median OS was 19.8 months (4 mg/kg) and 26.2 months (6 mg/kg).
- Grade ≥3 adverse events were higher in the 6 mg/kg cohort (76%) compared to 4 mg/kg (49%).
- The 6 mg/kg dose showed better efficacy but required careful monitoring and dose adjustments due to higher toxicity.
- 6 mg/kg is suggested as the preferred starting dose for Dato-DXd when combined with osimertinib.